3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
30
Neoplasms
11
Sarcoma
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
5
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Recurrence
2
Hemangiosarcoma
2
Financial Stress
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Ovarian Epithelial
2
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Diseases
1
Solid Tumours
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Patient Preference
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Plasma Cell
1
Melanoma
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
pembrolizumab
14
Nivolumab
13
Sunitinib
12
Axitinib
9
cabozantinib
8
belzutifan
8
Ipilimumab
7
Everolimus
5
atezolizumab
4
Sorafenib
4
temsirolimus
3
perifosine
3
motexafin gadolinium
3
Drug Therapy
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
lenvatinib
2
entinostat
2
ciforadenant
2
belinostat
2
avelumab
2
Paclitaxel
2
Immunotherapy
2
G250 monoclonal antibody
2
Fluorouracil
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Neoplasms
×
pazopanib
×
Clear all
NCT03200717
2023-08-21
IO-PAZ
Novartis
Phase 2
Completed
62 enrolled
12 charts